https://orcid.org/0000-0002-5113-9681
Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Joanna P. MacEwan, Syvart Dennen, Rebecca Kee, Farzad Ali, Jason Shafrin & Katharine Batt. (2020) Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016. Journal of Medical Economics 23:12, pages 1558-1569.
Read now
Read now
Articles from other publishers (7)
Frank R. Lichtenberg. (2023) The Relationship Between Pharmaceutical Innovation and Cancer Mortality in Spain, From 1999 to 2016. Value in Health 26:12, pages 1711-1720.
Crossref
Crossref
Yi-Chao Wang, Jing-Yan Tian, Ying-Ying Han, Yun-Fei Liu, Si-Yao Chen & Feng-Jun Guo. (2022) Evaluation of the potential of ultrasound-mediated drug delivery for the treatment of ovarian cancer through preclinical studies. Frontiers in Oncology 12.
Crossref
Crossref
Ana Beatriz D′Avó Luís & Mikyung Kelly Seo. (2021) Has the development of cancer biomarkers to guide treatment improved health outcomes?. The European Journal of Health Economics 22:5, pages 789-810.
Crossref
Crossref
Sebastian Böhm, Volker Grossmann & Holger Strulik. (2021) R&D-driven medical progress, health care costs, and the future of human longevity. The Journal of the Economics of Ageing 18, pages 100286.
Crossref
Crossref
Han Steutel. 2021. Arzneimittel-Kompass 2021. Arzneimittel-Kompass 2021
209
223
.
Oscar Arrieta, Rodrigo Catalán, Silvia Guzmán-Vazquez, Feliciano Barrón, Luis Lara-Mejía, Herman Soto-Molina, Maritza Ramos-Ramírez, Diana Flores-Estrada & Jaime de la Garza. (2020) Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations. BMC Cancer 20:1.
Crossref
Crossref
Katharina E. Blankart & Frank R. Lichtenberg. (2020) Are patients more adherent to newer drugs?. Health Care Management Science 23:4, pages 605-618.
Crossref
Crossref